TABLE 2. COVID-19 vaccine effectiveness* against COVID-19–associated hospitalization among adults without immunocompromising conditions, by vaccine product — 21 hospitals in 18 U.S. states,† March–August 2021.
Vaccine/Period | Vaccinated patients/Total patients (%) |
VE against COVID-19 hospitalization (95% CI) | |
---|---|---|---|
Case-patients | Control-patients | ||
Moderna VE after full vaccination
| |||
Full surveillance period§ |
54/1,517 (3.6) |
422/1,321 (31.9) |
93 (91–95) |
14–120 days after full vaccination |
36/1,499 (2.4) |
345/1,244 (27.7) |
93 (90–95) |
>120 days after full vaccination |
18/1,481 (1.2) |
77/976 (7.9) |
92 (87–96) |
Pfizer-BioNTech VE after full vaccination
| |||
Full surveillance period |
128/1,591 (8.0) |
610/1,509 (40.4) |
88 (85–91) |
14–120 days after full vaccination |
65/1,528 (4.3) |
495/1,394 (35.5) |
91 (88–93) |
>120 days after full vaccination |
63/1,526 (4.1) |
115/1,014 (11.3) |
77 (67–84) |
Janssen (Johnson & Johnson) VE after full vaccination
| |||
Full surveillance period |
37/1,500 (2.5) |
76/975 (7.8) |
71 (56–81) |
>28 days after full vaccination | 33/1,496 (2.2) | 59/958 (6.2) | 68 (49–80) |
Abbreviations: CI = confidence interval; VE = vaccine effectiveness.
* VE was estimated using logistic regression comparing the odds of being fully vaccinated with the Moderna, Pfizer-BioNTech or Janssen (Johnson & Johnson) COVID-19 vaccine versus being unvaccinated in case-patients and control-patients using the equation VE = 100 × (1 – odds ratio). Models were adjusted for date of hospital admission (biweekly intervals), U.S. Department of Health and Human Services region of hospital, age group (18–49, 50–64, ≥65 years), sex, and race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic of any race, non-Hispanic Other, or unknown). Binary time since full vaccination was added to the model with results for 14–120 days and >120 days shown.
† Hospitals by region included Northeast: Baystate Medical Center (Springfield, Massachusetts), Beth Israel Deaconess Medical Center (Boston, Massachusetts), Montefiore Medical Center (Bronx, New York); South: Vanderbilt University Medical Center (Nashville, Tennessee), University of Miami Medical Center (Miami, Florida), Emory University Medical Center (Atlanta, Georgia), Johns Hopkins Hospital (Baltimore, Maryland), Wake Forest University Baptist Medical Center (Winston-Salem, North Carolina), Baylor Scott & White Health (Temple, Texas); Midwest: University of Iowa Hospitals and Clinics (Iowa City, Iowa), University of Michigan Hospital (Ann Arbor, Michigan), Hennepin County Medical Center (Minneapolis, Minnesota), Barnes-Jewish Hospital (St. Louis, Missouri), Cleveland Clinic (Cleveland, Ohio), Ohio State University Wexner Medical Center (Columbus, Ohio); West: Stanford University Medical Center (Stanford, California), UCLA Medical Center (Los Angeles, California), UCHealth University of Colorado Hospital (Aurora, Colorado), Oregon Health & Science University Hospital (Portland, Oregon), Intermountain Medical Center (Murray, Utah), University of Washington (Seattle, Washington).
§ The full surveillance period included hospital admissions during March 11–August 15, 2021.